Kiniksa Pharmaceuticals International, plc (KNSA): who owns it and who trades it
As of Nov 16, 2026, KNSA insiders reported 89 open-market sales worth $122M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sanj K Patel (CEO), with $81.1M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Kiniksa Pharmaceuticals International
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KNSA
266 funds and institutions reported KNSA shares worth $3B at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $446M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 6.97M | – | $446M | +2% |
| Rubric Capital Management LP | 4.00M | – | $256M | +7% |
| Baker Bros. Advisors LP | 2.83M | – | $181M | +0% |
| BlackRock, Inc. | 2.74M | – | $175M | +463% |
| Tang Capital Management LLC | 2.26M | – | $145M | No change |
| Vanguard Portfolio Management LLC | 1.91M | – | $122M | +8% |
| Vanguard Capital Management LLC | 1.36M | – | $87M | +2% |
| Morgan Stanley | 1.01M | – | $64.7M | +1% |
| Arrowstreet Capital, Limited Partnership | 957,514 | – | $61.2M | +7% |
| Spruce Street Capital LP | 918,070 | – | $58.7M | +21% |
| Dimensional Fund Advisors LP | 874,786 | – | $55.9M | +8% |
| Invesco Ltd. | 772,806 | – | $49.4M | +2694% |
| Driehaus Capital Management LLC | 718,199 | – | $45.9M | +17% |
| State Street Corp | 704,194 | – | $45M | +819% |
| Acadian Asset Management LLC | 679,083 | – | $43.4M | -49% |
| Point72 Asset Management, L.P. | 659,493 | – | $42.2M | +3% |
| Rice Hall James & Associates, LLC | 624,928 | – | $40M | +3% |
| Pictet Asset Management Holding SA | 608,650 | – | $38.9M | -2% |
| Geode Capital Management, LLC | 604,180 | – | $38.6M | +1263% |
| Jupiter Topco LLC | 586,177 | – | $37.5M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KNSA insiders reported $0 of open-market purchases and $122M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 11,280 | $98.54 | $1.1M | Form 4 |
| Nov 4, 2026 | Sanj K Patel | CEO | Sale plan | 1,460 | $92.35 | $135K | Form 4 |
| Nov 4, 2026 | Sanj K Patel | CEO | Sale plan | 11,335 | $93.54 | $1.1M | Form 4 |
| Nov 4, 2026 | Sanj K Patel | CEO | Sale plan | 81,742 | $94.20 | $7.7M | Form 4 |
| Nov 4, 2026 | Sanj K Patel | CEO | Sale plan | 29,845 | $95.48 | $2.8M | Form 4 |
| Nov 4, 2026 | Sanj K Patel | CEO | Sale plan | 26,918 | $96.05 | $2.6M | Form 4 |
| Nov 3, 2026 | Sanj K Patel | CEO | Sale plan | 1,214 | $90.77 | $110K | Form 4 |
| Nov 3, 2026 | Sanj K Patel | CEO | Sale plan | 68,664 | $92.70 | $6.4M | Form 4 |
| Nov 3, 2026 | Sanj K Patel | CEO | Sale plan | 145,708 | $93.53 | $13.6M | Form 4 |
| Nov 3, 2026 | Sanj K Patel | CEO | Sale plan | 4,584 | $94.25 | $432K | Form 4 |
| Nov 2, 2026 | Sanj K Patel | CEO | Sale plan | 38,364 | $91.03 | $3.5M | Form 4 |
| Nov 2, 2026 | Sanj K Patel | CEO | Sale plan | 24,188 | $91.83 | $2.2M | Form 4 |
| Nov 2, 2026 | Sanj K Patel | CEO | Sale plan | 26,781 | $93.06 | $2.5M | Form 4 |
| Nov 2, 2026 | Sanj K Patel | CEO | Sale plan | 100 | $93.97 | $9.4K | Form 4 |
| Nov 2, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 899 | $92.37 | $83K | Form 4 |
| Nov 2, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 16,810 | $93.42 | $1.6M | Form 4 |
| Nov 2, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 704 | $94.09 | $66.2K | Form 4 |
| Nov 2, 2026 | Mark Ragosa | CFO | Sale plan | 14,027 | $91.40 | $1.3M | Form 4 |
| Nov 2, 2026 | Mark Ragosa | CFO | Sale plan | 10,502 | $92.03 | $966K | Form 4 |
| Nov 2, 2026 | Mark Ragosa | CFO | Sale plan | 12,034 | $93.13 | $1.1M | Form 4 |
| Nov 2, 2026 | Mark Ragosa | CFO | Sale plan | 220 | $94.01 | $20.7K | Form 4 |
| Nov 2, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 6,681 | $91.23 | $610K | Form 4 |
| Nov 2, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 8,932 | $92.05 | $822K | Form 4 |
| Nov 2, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 11,642 | $93.15 | $1.1M | Form 4 |
| Nov 2, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 722 | $94.05 | $67.9K | Form 4 |
| Oct 30, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 6,030 | $91.87 | $554K | Form 4 |
| Oct 30, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 6,831 | $92.77 | $634K | Form 4 |
| Oct 30, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 9,508 | $94.20 | $896K | Form 4 |
| Oct 30, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 3,705 | $94.86 | $351K | Form 4 |
| Oct 30, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 3,145 | $96.08 | $302K | Form 4 |
| Oct 30, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 1,691 | $97.11 | $164K | Form 4 |
| Oct 30, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 5,350 | $97.74 | $523K | Form 4 |
| Oct 30, 2026 | Sanj K Patel | CEO | Sale plan | 41,169 | $92.01 | $3.8M | Form 4 |
| Oct 30, 2026 | Sanj K Patel | CEO | Sale plan | 18,685 | $92.77 | $1.7M | Form 4 |
| Oct 30, 2026 | Sanj K Patel | CEO | Sale plan | 15,903 | $93.62 | $1.5M | Form 4 |
| Oct 30, 2026 | Sanj K Patel | CEO | Sale plan | 8,888 | $94.72 | $842K | Form 4 |
| Oct 30, 2026 | Sanj K Patel | CEO | Sale plan | 4,490 | $95.97 | $431K | Form 4 |
| Oct 30, 2026 | Sanj K Patel | CEO | Sale plan | 2,316 | $97.34 | $225K | Form 4 |
| Oct 30, 2026 | Sanj K Patel | CEO | Sale plan | 1,440 | $98.16 | $141K | Form 4 |
| Oct 30, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 41,789 | $92.02 | $3.8M | Form 4 |
| Oct 30, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 16,056 | $92.85 | $1.5M | Form 4 |
| Oct 30, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 6,841 | $93.91 | $642K | Form 4 |
| Oct 30, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 4,821 | $94.86 | $457K | Form 4 |
| Oct 30, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 4,000 | $95.97 | $384K | Form 4 |
| Oct 30, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 1,925 | $97.06 | $187K | Form 4 |
| Oct 30, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 2,155 | $97.77 | $211K | Form 4 |
| Oct 30, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 37,775 | $92.00 | $3.5M | Form 4 |
| Oct 30, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 15,114 | $92.81 | $1.4M | Form 4 |
| Oct 30, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 8,430 | $93.97 | $792K | Form 4 |
| Oct 30, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 6,282 | $94.92 | $596K | Form 4 |
| Oct 30, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 3,672 | $96.03 | $353K | Form 4 |
| Oct 30, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 1,760 | $97.10 | $171K | Form 4 |
| Oct 30, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 2,575 | $97.76 | $252K | Form 4 |
| Sep 3, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 4,600 | $80.30 | $369K | Form 4 |
| Jul 29, 2026 | G Bradley Cole | Director | Sale | 3,673 | $81.43 | $299K | Form 4 |
| May 1, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 37,327 | $53.52 | $2M | Form 4 |
| May 1, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 21,097 | $54.04 | $1.1M | Form 4 |
| May 1, 2026 | Sanj K Patel | CEO | Sale plan | 48,565 | $54.02 | $2.6M | Form 4 |
| Apr 30, 2026 | Sanj K Patel | CEO | Sale plan | 2,141 | $54.01 | $116K | Form 4 |
| Apr 29, 2026 | Sanj K Patel | CEO | Sale plan | 22,544 | $54.01 | $1.2M | Form 4 |
| Apr 28, 2026 | Sanj K Patel | CEO | Sale plan | 51,750 | $54.02 | $2.8M | Form 4 |
| Apr 28, 2026 | Sanj K Patel | CEO | Sale plan | 243,596 | $52.02 | $12.7M | Form 4 |
| Apr 28, 2026 | Sanj K Patel | CEO | Sale plan | 113,673 | $51.47 | $5.9M | Form 4 |
| Apr 28, 2026 | Sanj K Patel | CEO | Sale plan | 74,635 | $50.43 | $3.8M | Form 4 |
| Apr 28, 2026 | Barry D Quart | Director | Sale plan | 13,099 | $50.10 | $656K | Form 4 |
| Apr 9, 2026 | Michael R Megna | CHIEF ACCOUNTING OFFICER | Sale plan | 6,625 | $46.69 | $309K | Form 4 |
| Apr 9, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 1,703 | $46.69 | $79.5K | Form 4 |
| Apr 6, 2026 | Sanj K Patel | CEO | Sale plan | 7,278 | $50.01 | $364K | Form 4 |
| Apr 6, 2026 | Ross Moat | CHIEF OPERATING OFFICER | Sale plan | 2,367 | $48.58 | $115K | Form 4 |
| Apr 6, 2026 | Barry D Quart | Director | Sale plan | 6,901 | $50.00 | $345K | Form 4 |
| Mar 9, 2026 | Mark Ragosa | CFO | Sale plan | 18,741 | $46.24 | $867K | Form 4 |
| Mar 9, 2026 | Mark Ragosa | CFO | Sale plan | 17,981 | $45.58 | $820K | Form 4 |
| Mar 2, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 5,714 | $45.92 | $262K | Form 4 |
| Mar 2, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 22,223 | $44.88 | $997K | Form 4 |
| Mar 2, 2026 | John F. Paolini | CHIEF MEDICAL OFFICER | Sale plan | 12,063 | $44.20 | $533K | Form 4 |
| Feb 12, 2026 | Barry D Quart | Director | Sale plan | 2,690 | $45.00 | $121K | Form 4 |
| Feb 10, 2026 | Barry D Quart | Director | Sale plan | 110 | $45.00 | $5K | Form 4 |
| Feb 9, 2026 | Mark Ragosa | CFO | Sale plan | 9,114 | $42.85 | $391K | Form 4 |
| Feb 9, 2026 | Mark Ragosa | CFO | Sale plan | 8,731 | $43.72 | $382K | Form 4 |
| Feb 4, 2026 | Barry D Quart | Director | Sale plan | 2,602 | $45.02 | $117K | Form 4 |
| Feb 3, 2026 | Barry D Quart | Director | Sale plan | 12,528 | $45.27 | $567K | Form 4 |
| Feb 2, 2026 | Barry D Quart | Director | Sale plan | 830 | $45.00 | $37.4K | Form 4 |
| Jan 8, 2026 | Mark Ragosa | CFO | Sale plan | 12,000 | $41.89 | $503K | Form 4 |
| Dec 15, 2025 | Barry D Quart | Director | Sale plan | 20,129 | $41.51 | $836K | Form 4 |
| Dec 15, 2025 | Eben Tessari | CHIEF OPERATING OFFICER | Sale plan | 12,048 | $41.56 | $501K | Form 4 |
| Dec 8, 2025 | Mark Ragosa | CFO | Sale plan | 42,841 | $41.49 | $1.8M | Form 4 |
| Nov 26, 2025 | Eben Tessari | CHIEF OPERATING OFFICER | Sale plan | 200 | $42.89 | $8.6K | Form 4 |
| Nov 17, 2025 | Eben Tessari | CHIEF OPERATING OFFICER | Sale plan | 645 | $40.08 | $25.9K | Form 4 |
| Nov 17, 2025 | Eben Tessari | CHIEF OPERATING OFFICER | Sale plan | 11,825 | $41.30 | $488K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sanj K Patel | CHAIRMAN & CEO, Director | – | $81.1M | Nov 4, 2026 |
| John F. Paolini | CHIEF MEDICAL OFFICER | – | $13.9M | Nov 2, 2026 |
| Ross Moat | CHIEF OPERATING OFFICER | – | $9.8M | Nov 2, 2026 |
| Mark Ragosa | CHIEF FINANCIAL OFFICER | – | $8.1M | Nov 2, 2026 |
| Michael R Megna | CHIEF ACCOUNTING OFFICER | – | $5.2M | Nov 9, 2026 |
| Barry D Quart | Director | – | $2.7M | Apr 28, 2026 |
| Eben Tessari | CHIEF OPERATING OFFICER | – | $1M | Dec 15, 2025 |
| G Bradley Cole | Director | – | $299K | Jul 29, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KNSA short interest
4.29M KNSA shares are sold short. Over the last 12 reports the number of shares short went up 35%.
As of Oct 30, 2026, 4.29M KNSA shares were sold short, up 14.1% from the report before. At the average daily volume of 1.10M shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.29M | – | +14% | 1.10M | 3.9 |
| Oct 15, 2026 | 3.76M | – | -0% | 555,480 | 6.8 |
| Sep 30, 2026 | 3.78M | – | -3% | 589,057 | 6.4 |
| Sep 15, 2026 | 3.88M | – | +2% | 537,855 | 7.2 |
| Aug 31, 2026 | 3.79M | – | -12% | 436,050 | 8.7 |
| Aug 14, 2026 | 4.28M | – | -1% | 447,952 | 9.6 |
| Jul 31, 2026 | 4.32M | – | -4% | 865,012 | 5.0 |
| Jul 15, 2026 | 4.51M | – | +9% | 658,502 | 6.8 |
| Jun 30, 2026 | 4.15M | – | +41% | 1.44M | 2.9 |
| Jun 15, 2026 | 2.95M | – | -3% | 514,615 | 5.7 |
| May 29, 2026 | 3.04M | – | -4% | 547,377 | 5.6 |
| May 15, 2026 | 3.18M | – | -10% | 572,484 | 5.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Kiniksa Pharmaceuticals International company events
Kiniksa Pharmaceuticals International filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 27, 2026.
- Oct 27, 2026ResultsReleased financial results. Filing
- Oct 22, 2026LeadershipThe Compensation Committee of the Board of Directors of Kiniksa Pharmaceuticals International, plc appointed Ross Moat as President and Chief Operating Officer, effective immediately. Filing
- Jul 28, 2026ResultsReleased financial results. Filing
- May 29, 2026VoteReported shareholder vote results. Filing
- May 26, 2026AgreementKiniksa Pharmaceuticals International, plc entered into a deed of waiver with Baker Bros. Filing
- May 1, 2026LeadershipEben Tessari informed Kiniksa Pharmaceuticals International, plc of his decision to resign as Chief Strategy Officer of the Company to pursue another executive position within the life sciences industry. Filing
- Apr 28, 2026ResultsReleased financial results. Filing
- Feb 24, 2026ResultsReleased financial results. Filing
- Jan 14, 2026LeadershipThe Board of Directors of Kiniksa Pharmaceuticals International, plc appointed Ross Moat to the position of Chief Operating Officer and principal operating officer. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Kiniksa Pharmaceuticals International financials
Famous investors that hold KNSA
5 of the 50 well-known investors we track reported holding KNSA in their latest 13F filing. The largest position is Steve Cohen's, worth $40.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 548,496 | $40.9M | 0.1% | -17% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 421,176 | $31.4M | 0.0% | +911% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 323,808 | $24.2M | 0.0% | -19% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 165,477 | $12.3M | 0.0% | +143% |
| Israel Englander · Millennium Management | Q3 2026 | 95,826 | $7.1M | 0.0% | +3% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KNSA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Rubric Capital Management LP | 13G/A | 5.8% |
| Nov 16, 2026 | Rubric Capital Management LP | 13G/A | 5.8% |
Questions about Kiniksa Pharmaceuticals International, plc (KNSA) stock
Who owns the most KNSA stock?
The largest reported owner of Kiniksa Pharmaceuticals International, plc (KNSA) is FMR LLC (Fidelity). In total, 266 funds and institutions reported holding KNSA at the end of Q2 2026. See the largest owners.
Are KNSA insiders buying or selling?
In the last 12 months, KNSA insiders reported no open-market purchases and 89 sales worth $122M. The latest trade was on Nov 9, 2026. See every trade.
What is the short interest in KNSA?
As of Oct 30, 2026, 4.29M KNSA shares were sold short, up 14.1% from the report before. At the average daily volume of 1.10M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Which famous investors hold KNSA?
5 of the 50 well-known investors we track reported KNSA in their latest 13F filing, including Steve Cohen, Ken Griffin, Ken Fisher. The largest position is worth $40.9M. See all holders.
Executive pay
Kiniksa Pharmaceuticals International's chief executive was paid a total of $10.8M for the year ended Dec 31, 2025, up 54% from $7M the year before. In the last 12 months, Kiniksa Pharmaceuticals International's executives and directors bought no stock on the open market and sold $122M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.